Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Jan 15;23(2):303-12.
doi: 10.1111/j.1365-2036.2006.02743.x.
S Bar-Meir, A Lavy, O Mickisch, Z Tulassay, L Pronai, L Kupcinskas, G Kiudelis, J Pokrotnieks, A Kovács, M Faszczyk, A Razbadauskas, B Margus, M Stolte, R Müller, R Greinwald; International Budesonide Foam Study Group
Affiliations
- PMID: 16393311
- DOI: 10.1111/j.1365-2036.2006.02743.x
Free article
Randomized Controlled Trial
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
V Gross et al. Aliment Pharmacol Ther. 2006.
Free article
Abstract
Background: Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis.
Aim: To compare the therapeutic efficacy, tolerability and safety, and patient's preference of budesonide foam vs. budesonide enema.
Methods: Patients with active ulcerative proctitis or proctosigmoiditis (clinical activity index > 4 and endoscopic index > or = 4) were eligible for this double-blind, double-dummy, randomized, multicentre study. They received 2 mg/25 mL budesonide foam and placebo enema (n = 265), or 2 mg/100 mL budesonide enema and placebo foam (n = 268) for 4 weeks. Primary endpoint was clinical remission (clinical activity index < or = 4) at the final/withdrawal visit (per protocol).
Results: A total of 541 patients were randomized--533 were evaluable for intention-to-treat analysis and 449 for per protocol analysis. Clinical remission rates (per protocol) were 60% for budesonide foam and 66% for budesonide enema (P = 0.02362 for non-inferiority of foam vs. enema within a predefined non-inferiority margin of 15%). Both formulations were safe and no drug-related serious adverse events were observed. Because of better tolerability and easier application most patients preferred foam (84%).
Conclusion: Budesonide foam is as effective as budesonide enema in the treatment of active ulcerative proctitis or proctosigmoiditis. Both budesonide formulations are safe, and most patients prefer foam.
Similar articles
- Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Ardizzone S, Doldo P, Ranzi T, Sturniolo GC, Giglio LA, Annese V, D'Arienzo A, Gaia E, Gullini S, Riegler G, Valentini M, Massa P, Del Piano M, Rossini F, Guidetti CS, Pera A, Greinwald R, Bianchi Porro G. Ardizzone S, et al. Ital J Gastroenterol Hepatol. 1999 Nov;31(8):677-84. Ital J Gastroenterol Hepatol. 1999. PMID: 10730559 Clinical Trial. - Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lémann M. Cortot A, et al. Am J Gastroenterol. 2008 Dec;103(12):3106-14. doi: 10.1111/j.1572-0241.2008.02152.x. Am J Gastroenterol. 2008. PMID: 19086960 Clinical Trial. - [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
Rufle W, Frühmorgen P, Huber W, Kimmig JM. Rufle W, et al. Z Gastroenterol. 2000 Apr;38(4):287-93. doi: 10.1055/s-2000-14869. Z Gastroenterol. 2000. PMID: 10820860 Clinical Trial. German. - Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
Bitton A. Bitton A. Semin Gastrointest Dis. 2001 Oct;12(4):263-74. Semin Gastrointest Dis. 2001. PMID: 11726080 Review. - Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM, McTavish D. Spencer CM, et al. Drugs. 1995 Nov;50(5):854-72. doi: 10.2165/00003495-199550050-00006. Drugs. 1995. PMID: 8586030 Review.
Cited by
- A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.
Feng S, Zhang Y, Hou C, Liu Y, Gao Y, Song Y, Luo J. Feng S, et al. Sci Adv. 2024 Aug 30;10(35):eadn8695. doi: 10.1126/sciadv.adn8695. Epub 2024 Aug 28. Sci Adv. 2024. PMID: 39196940 Free PMC article. - Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Aruljothy A, Singh S, Narula N, Moran GW, Vuyyuru SK, Hogan M, Zayadi A, MacDonald JK, Caron B, Danese S, Peyrin Biroulet L, Ma C, Jairath V. Aruljothy A, et al. Aliment Pharmacol Ther. 2023 Oct;58(8):740-762. doi: 10.1111/apt.17666. Epub 2023 Aug 17. Aliment Pharmacol Ther. 2023. PMID: 37589498 Free PMC article. Review. - Patients' Preference of Topical Therapy for Ulcerative Colitis in Japan: A Web-based 3T Survey.
Yanai S, Toya Y, Nakamura S, Matsumoto T. Yanai S, et al. Crohns Colitis 360. 2020 Apr 17;2(2):otaa030. doi: 10.1093/crocol/otaa030. eCollection 2020 Apr. Crohns Colitis 360. 2020. PMID: 36798649 Free PMC article. - Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L, Sobon M, Delmans G, Maksyashina SV, Sablin OA, Pokrotnieks J, Mostovoy Y, Datsenko O, Abdulkhakov S, Dorofeyev A, Levchenko O, Alexeeva O, Andreev P, Kolesnik IP, Mihaly E, Abrahamovych O, Baluta M, Kharchenko N, Viacheslav N, Uspenskiy Y, Vieth M, Mohrbacher R, Mueller R, Greinwald R. Kruis W, et al. J Crohns Colitis. 2022 Nov 23;16(11):1714-1724. doi: 10.1093/ecco-jcc/jjac081. J Crohns Colitis. 2022. PMID: 35709376 Free PMC article. Clinical Trial. - Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?
Sood A, Mahajan R, Singh A, Midha V, Mehta V. Sood A, et al. Intest Res. 2022 Jul;20(3):297-302. doi: 10.5217/ir.2021.00099. Epub 2022 Feb 8. Intest Res. 2022. PMID: 35124950 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources